Long‑term statin use before primary percutaneous coronary intervention improves treatment outcomes of acute myocardial infarction

  • Authors:
    • Ruiwei Guo
    • Lixia Yang
    • Lihua Mu
    • Xianfeng Pan
    • Feng Qi
  • View Affiliations

  • Published online on: February 22, 2017     https://doi.org/10.3892/etm.2017.4156
  • Pages: 1578-1583
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Numerous studies have reported that high-dose statin loading therapy prior to primary percutaneous coronary intervention (PPCI) improves the clinical outcomes of patients following acute myocardial infarction (AMI). However, little is known about the effects of long‑term statin use prior to PPCI on such outcomes. Therefore, the aim of the present analysis was to clarify the effects of long‑term statin use before PPCI on the treatment outcomes of patients following AMI. The records of 213 patients who had AMI and met the inclusion criteria were retrospectively reviewed. Patients were divided into two groups: A control group (n=178) who had received no statin pretreatment before AMI onset, and a statin group (n=35) who had received statin treatment for ≥1 month before AMI onset. All patients received a standard treatment regimen for the secondary prevention of coronary artery disease after PPCI. Baseline clinical variables, details of the PPCI procedure and clinical outcomes within 3 months after treatment were reviewed. Patients in the statin group were significantly older than those in the control group (P=0.003). Compared with the control group, there was a greater proportion of patients with hyperlipidemia and previous angina pectoris in the statin group. There were no differences in the use of other drugs (aspirin, β‑blockers and angiotensin‑converting enzyme inhibitors) prior to PPCI between the two groups. The corrected TIMI frame count (cTFC) was significantly lower in the statin group than in the control group (24.1±12.8 vs. 29.4±14.3, respectively; P=0.043). Multivariable linear regression analysis showed that long‑term statin use before AMI was a significant predictor of cTFC after PPCI (P=0.012). Furthermore, the incidence of major adverse cardiac events within 3 months after PPCI was higher in the control group than in the statin group (16.8 vs. 2.9%, respectively; P=0.032). Logistic regression analysis showed that previous statin use was associated with the incidence of major adverse cardiac events within 3 months after treatment (P=0.012). The results of the present study demonstrate that long‑term statin use prior to PPCI improved treatment outcomes after AMI in actual clinical practice.
View References

Related Articles

Journal Cover

April-2017
Volume 13 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Guo R, Yang L, Mu L, Pan X and Qi F: Long‑term statin use before primary percutaneous coronary intervention improves treatment outcomes of acute myocardial infarction. Exp Ther Med 13: 1578-1583, 2017
APA
Guo, R., Yang, L., Mu, L., Pan, X., & Qi, F. (2017). Long‑term statin use before primary percutaneous coronary intervention improves treatment outcomes of acute myocardial infarction. Experimental and Therapeutic Medicine, 13, 1578-1583. https://doi.org/10.3892/etm.2017.4156
MLA
Guo, R., Yang, L., Mu, L., Pan, X., Qi, F."Long‑term statin use before primary percutaneous coronary intervention improves treatment outcomes of acute myocardial infarction". Experimental and Therapeutic Medicine 13.4 (2017): 1578-1583.
Chicago
Guo, R., Yang, L., Mu, L., Pan, X., Qi, F."Long‑term statin use before primary percutaneous coronary intervention improves treatment outcomes of acute myocardial infarction". Experimental and Therapeutic Medicine 13, no. 4 (2017): 1578-1583. https://doi.org/10.3892/etm.2017.4156